Company
Allogene Therapeutics
Allogene Therapeutics has 8 drugs tracked on RxWires: 2 in Phase 2, 2 in Phase 1/2, 4 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ALLO-647 | Phase 2 | Relapsed/Refractory Large B Cell Lymphoma |
| cemacabtagene ansegedleucel | Phase 2 | Large B-cell Lymphoma |
| ALLO-605 | Phase 1/2 | Relapsed/Refractory Multiple Myeloma |
| ALLO-501A | Phase 1/2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma |
| ALLO-329 | Phase 1 | Systemic Lupus Erythematosus (With and Without Nephritis) |
| ALLO-501 | Phase 1 | Relapsed/Refractory Large B Cell Lymphoma |
| ALLO-316 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma |
| ALLO-715 | Phase 1 | Relapsed/Refractory Multiple Myeloma |
Latest
- allogene therapeutics filed 8-K
- allogene therapeutics filed 8-K
- allogene therapeutics filed 8-K
- allogene therapeutics filed 8-K
- allogene therapeutics filed 8-K
Follow Allogene Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.